Ronald F van Vollenhoven

Ronald F van Vollenhoven

UNVERIFIED PROFILE

Are you Ronald F van Vollenhoven?   Register this Author

Register author
Ronald F van Vollenhoven

Ronald F van Vollenhoven

Publications by authors named "Ronald F van Vollenhoven"

Are you Ronald F van Vollenhoven?   Register this Author

100Publications

2845Reads

-Profile Views

The relationship between remission and health-related quality of life in a cohort of SLE patients.

Rheumatology (Oxford) 2019 Apr;58(4):628-635

Department of Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
https://academic.oup.com/rheumatology/article/58/4/628/52308
Publisher Site
http://dx.doi.org/10.1093/rheumatology/key349DOI Listing
April 2019

Construction of a frailty index as a novel health measure in systemic lupus erythematosus.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

Department of Medicine, Division of Rheumatology, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Community Health & Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada; Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea;Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico; Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA; Division of Rheumatology, CHU de Québec et Université Laval, Quebec City, Canada; Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, ON, Canada; Arthritis Research UK Epidemiology Unit, Faculty of Biology Medicine and Health, Manchester Academic Health Sciences Center, The University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Center Manchester, UK; Center for Rheumatology, Department of Medicine, University College London, UK; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, King's College London School of Medicine, UK, London, UK; Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA; Northwestern University and Feinberg School of Medicine, Chicago, IL, USA; Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA, USA; Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland UK; Feinstein Institute for Medical Research, Manhasset, NY, USA; Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain; Emory University School of Medicine, Division of Rheumatology, Atlanta, Georgia, USA Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey; Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden; Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden. Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain; Medical University of South Carolina, Charleston, South Carolina, USA; UCSD School of Medicine, La Jolla, CA, USA; Copenhagen Lupus and Vasculitis Clinic, 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; University of Manitoba, Winnipeg, Manitoba, Canada; Hospital for Joint Diseases, NYU, Seligman Center for Advanced Therapeutics, New York NY; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada. Funding for this work was provided by the Nova Scotia Health Authority Research Fund. Dr. Sang-Cheol Bae's work was supported in part by NRF-2017M3A9B4050335, Republic of Korea. Dr. Caroline Gordon's work was supported by Lupus UK and the NIHR /Wellcome Trust Clinical Research Facility. The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Paul R. Fortin presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Université Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is a National Institute for Health Research (NIHR) Senior Investigator and is supported by Arthritis Research UK, the NIHR Manchester Biomedical Centre and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Dr Isenberg and Dr Rahman are supported by and supported by the National Institute for Health, Research University College London Hospitals Biomedical Research Center. The Hopkins Lupus Cohort is supported by the NIH (grant AR43727 and 69572). Dr. Mary Anne Dooley's work was supported by the NIH (grant RR00046). Dr. Ramsey-Goldman's work was supported by the NIH (grants 5UL1TR001422-02, formerly 8UL1TR000150 and UL-1RR-025741, K24-AR-02318, and P60AR064464 formerly P60-AR- 48098). Dr. Ruiz-Irastorza is supported by the Department of Education, Universities and Research of the Basque Government. Dr. Soren Jacobsen is supported by the Danish Rheumatism Association (A3865) and the Novo Nordisk Foundation (A05990). Dr. John G. Hanly is supported by the Canadian Institutes of Health Research (grant MOP-88526). Address Correspondence to: Dr. John G Hanly, Division of Rheumatology, Nova Scotia Rehabilitation Centre (2nd Floor), 1341 Summer Street, Halifax, Nova Scotia, Canada, B3H 4K4.Email:

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.181338
Publisher Site
http://dx.doi.org/10.3899/jrheum.181338DOI Listing
April 2019

Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis.

Front Immunol 2019 24;10:902. Epub 2019 Apr 24.

Amsterdam UMC, Vrije Universiteit Amsterdam, Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00902DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491736PMC
April 2019

Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial.

J Rheumatol 2019 Feb 1. Epub 2019 Feb 1.

From the Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Crescendo Bioscience, South San Francisco, California, USA; Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Amsterdam Rheumatology and Immunology Center, Amsterdam, the Netherlands; Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden. This work was supported in part by a grant from the Swedish Rheumatism Association. Some of the authors were supported by clinical research funds from Stockholm County (ALF funds). An annual unrestricted grant was provided by Schering-Plough Sweden, which was used to support a study coordinator and a medical monitor for the original clinical trial. RJB received consultancy fees from Crescendo Bioscience. K. Hambardzumyan, MSc, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital; R.J. Bolce, MSN, Crescendo Bioscience; J.K. Wallman, MD, PhD, Section of Rheumatology, Department of Clinical Sciences Lund, Lund University; R.F. van Vollenhoven, MD, PhD, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, and Amsterdam Rheumatology and Immunology Center; S. Saevarsdottir, MD, PhD, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, and Unit of Translational Epidemiology, Institute of Environmental Medicine, Karolinska Institutet. Address correspondence to Dr. S. Saevarsdottir, Unit of Translational Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, SE-17165, Solna, Stockholm, Sweden. E-mail: Accepted for publication October 9, 2018.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.180537
Publisher Site
http://dx.doi.org/10.3899/jrheum.180537DOI Listing
February 2019

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Sci Transl Med 2019 Jan;11(477)

Department of Immunopathology, Sanquin Research, 1066 CX Amsterdam, Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aa
Publisher Site
http://dx.doi.org/10.1126/scitranslmed.aat3356DOI Listing
January 2019

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.

Expert Opin Biol Ther 2018 Dec 20. Epub 2018 Dec 20.

a Division of Rheumatology, Department of Medicine , Karolinska Institutet , Stockholm , Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1561856DOI Listing
December 2018

Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis.

Curr Opin Rheumatol 2018 07;30(4):340-346

Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000516DOI Listing
July 2018

Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort.

Int J Rheumatol 2018 11;2018:9152480. Epub 2018 Jun 11.

Eugeniahemmet, T2, Karolinska Universitetssjukhuset, Solna, 17176 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/9152480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016163PMC
June 2018

Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback.

Clin Exp Rheumatol 2018 Jan-Feb;36(1):21-28. Epub 2017 Jun 5.

Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
April 2018

Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.

Clin Exp Rheumatol 2016 Nov-Dec;34(6):1065-1071. Epub 2016 Aug 31.

Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; and School of Medicine, University of Tampere, Finland.

View Article

Download full-text PDF

Source
June 2017

Editorial: Who Gets Lupus? Clues to a Tantalizing Syndrome.

Arthritis Rheumatol 2017 03;69(3):483-486

Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40005DOI Listing
March 2017

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort.

Lupus Sci Med 2017 8;4(1):e000192. Epub 2017 Feb 8.

Division of Rheumatology , School of Medicine, Johns Hopkins University , Baltimore, MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2016-000192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307372PMC
February 2017

Reply.

Arthritis Care Res (Hoboken) 2016 07;68(7):1051

Karolinska Institute, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.22809DOI Listing
July 2016

New therapeutic approaches in rheumatoid arthritis.

Presse Med 2016 Jun 27;45(6 Pt 2):e179-92. Epub 2016 May 27.

Department of Medicine, Karolinska Institute, Unit for Clinical Research Therapy, Inflammatory Diseases (ClinTrid), D1:00, Karolinska Universitetssjukhustet 171 76, Stockholm, Sweden. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2016.05.004DOI Listing
June 2016

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

RMD Open 2016 10;2(1):e000213. Epub 2016 May 10.

Karolinska Institute, Stockholm, Sweden; Amsterdam Rheumatology and Immunology Center ARC Academic Medical Center, Amsterdam.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2015-000213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874056PMC
June 2016

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.

RMD Open 2016 1;2(1):e000197. Epub 2016 Mar 1.

Unit of Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine , Karolinska Institutet, Karolinska University Hospital , Stockholm , Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2015-000197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780313PMC
March 2016

Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.

Ann Rheum Dis 2015 Dec 4;74(12):2260-1. Epub 2015 Sep 4.

Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2015-207814DOI Listing
December 2015

Remission in SLE: closing in on the target.

Ann Rheum Dis 2015 Dec 28;74(12):2103-6. Epub 2015 Oct 28.

Center for Autoimmune and Musculoskeletal, The Feinstein Institute for Medical Research, Manhasset, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2015-208231DOI Listing
December 2015

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.

J Rheumatol 2015 Dec 1;42(12):2288-95. Epub 2015 Nov 1.

From the Division of Pediatric Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian Hospital/Columbia University Medical Center; New York University Langone Medical Center; Division of Rheumatology, New York-Presbyterian Hospital/Columbia University Medical Center, New York; Hofstra North Shore-LIJ School of Medicine, Hempstead, New York; Medical University of South Carolina, Charleston, South Carolina; Temple University School of Medicine, Philadelphia, Pennsylvania; Johns Hopkins University School of Medicine, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Karolinska University Hospital, Stockholm, Sweden; Cedars-Sinai Medical Center, Los Angeles, California, USA.J.S. Hui-Yuen, MD, MSc, Fellow, Division of Pediatric Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian Hospital/Columbia University Medical Center; A. Reddy, BSc, Research Assistant, New York University Langone Medical Center; J. Taylor, MD, Pediatric Resident, Division of Pediatric Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian Hospital/Columbia University Medical Center; X. Li, BSc, Research Assistant, Division of Rheumatology, New York-Presbyterian Hospital/Columbia University Medical Center; A.H. Eichenfield, MD, Assistant Professor, Division of Pediatric Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian Hospital/Columbia University Medical Center; L.M. Bermudez, MD, Fellow, Division of Pediatric Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian Hospital/Columbia University Medical Center; A.J. Starr, MD, Assistant Professor, Division of Pediatric Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian Hospital/Columbia University Medical Center; L.F. Imundo, MD, Division of Rheumatology, New York-Presbyterian Hospital/Columbia University Medical Center; J. Buyon, MD, Professor, New York University Langone Medical

View Article

Download full-text PDF

Source
http://www.jrheum.org/cgi/doi/10.3899/jrheum.150470
Publisher Site
http://dx.doi.org/10.3899/jrheum.150470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031077PMC
December 2015

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.

J Rheumatol 2015 Oct 15;42(10):1761-6. Epub 2015 Aug 15.

From the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas; Department of Rheumatology, University of California, Los Angeles Medical Center, Los Angeles, California, USA; Roche Products Ltd., Welwyn Garden City, UK.R.F. van Vollenhoven, MD, Chief of the Unit for Clinical Therapy Research, Inflammatory Disease, Karolinska Institute; R.M. Fleischmann, MD, Clinical Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center; D.E. Furst, MD, Carl M. Pearson Professor of Medicine, Department of Rheumatology, University of California, Los Angeles Medical Center; S. Lacey, MSc, Statistician, Roche Products Ltd.; P.B. Lehane, PhD, Senior Clinical Development Scientist, Roche Products Ltd.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.150051
Publisher Site
http://dx.doi.org/10.3899/jrheum.150051DOI Listing
October 2015

Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.

BMC Med 2015 Sep 30;13:247. Epub 2015 Sep 30.

Department of Rheumatology and Inflammation Research, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12916-015-0485-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589197PMC
September 2015

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

Arthritis Res Ther 2015 Aug 3;17:181. Epub 2015 Aug 3.

Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, 17176, Sweden.

View Article

Download full-text PDF

Source
http://arthritis-research.com/content/17/1/181
Publisher Site
http://dx.doi.org/10.1186/s13075-015-0707-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522973PMC
August 2015

Rituximab and lupus--a promising pair?

Curr Rheumatol Rep 2014 ;16(9):444

Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Karolinska Institute, 171 76, Stockholm, Sweden,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-014-0444-5DOI Listing
February 2015

Advances in the treatment of rheumatoid arthritis.

F1000Prime Rep 2014 6;6:31. Epub 2014 May 6.

Department of Medicine, Unit of Clinical Therapy Research in Inflammatory Diseases (ClinTRID) Karolinska University Hospital, D2:00, 171 76 Stockholm Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12703/P6-31DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017904PMC
June 2014

Tofacitinib versus methotrexate in rheumatoid arthritis.

N Engl J Med 2014 Jun;370(25):2377-86

From Seoul National University College of Medicine, Seoul, South Korea (E.B.L.); Metroplex Clinical Research Center, Dallas (R.F.); Cabrini Health and Monash University, Melbourne, VIC, Australia (S.H.); Pfizer, Groton, CT (B.W., J.D.B., D.G., S.K., G.V.W., C.Z., S.H.Z.); Pfizer, New York (T.K.); and Karolinska Institute, Stockholm (R.F.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1310476DOI Listing
June 2014

Early start and stop of biologics: has the time come?

BMC Med 2014 Feb 6;12:25. Epub 2014 Feb 6.

Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm 17176, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1741-7015-12-25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915229PMC
February 2014

Case 16-2013: A girl with irritability, hypersomnia, and somatic symptoms.

N Engl J Med 2013 09;369(12):1174

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1307922DOI Listing
September 2013

Biologics in SLE: towards new approaches.

Best Pract Res Clin Rheumatol 2013 Jun;27(3):341-9

The Karolinska Institute, Stockholm, Sweden. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2013.07.006DOI Listing
June 2013